Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.

If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated.

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.

In patients with muscle-invasive bladder cancer, Imfinzi reduced the risk of disease recurring by 32% when given alongside the current standard of care, interim analysis of a late-stage trial found. The medicine also reduced the risk of death by a quarter when added to current treatments such as chemotherapy and surgery,

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.